| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 78.42 | 1.3% | 8.9% |
| Total Income | 78.42 | 1.3% | 8.9% |
| Expenditure | 91.37 | 6.8% | 11.4% |
| PBT | -8.07 | 26.9% | 83.0% |
| Net Profit | -8.08 | 27.2% | 83.2% |
| OPM | -16.51% | 8.80pp | 2.66pp |
| NPM | -10.31% | 2.31pp | 4.19pp |
| EPS | -0.19 | 26.7% | 72.7% |
AngioDynamics Reports Q3 FY26 Financial Results; Med Tech Growth Drives Profitability
03 May 2026 · 3 May, 7:21 pm
Summary
AngioDynamics reported net sales of $78.4 million for the third quarter of fiscal year 2026, representing an 8.9% increase compared to the prior-year quarter. Med Tech net sales increased by 19.0% to $37.3 million, driven by strong performance in Auryon, Mechanical Thrombectomy, and NanoKnife sales. The company's adjusted EBITDA for the quarter was $1.8 million, up from $1.3 million in the prior-year period. AngioDynamics raised its full year FY 2026 guidance for net sales and Adjusted EBITDA.
Key Highlights
- 1
Net sales for the third quarter of fiscal year 2026 were $78.4 million, an increase of 8.9% compared to the prior-year quarter.
- 2
Med Tech net sales were $37.3 million, a 19.0% increase from $31.3 million in the prior-year period.
- 3
Auryon sales were $16.3 million, an increase of 17.9% compared to the prior-year quarter.
- 4
Mechanical Thrombectomy business delivered sales of $11.5 million, an increase of 17.9% compared to the prior-year quarter.
- 5
NanoKnife sales were $7.6 million, an increase of 21.0% compared to the prior-year quarter.
- 6
Adjusted EBITDA in the third quarter of fiscal 2026 was $1.8 million, compared to $1.3 million in the third quarter of fiscal 2025.
- 7
The company increased full year FY 2026 guidance for net sales to $313.5 - $315.5 M and Adjusted EBITDA to $10.0 - $12.0 M.
Management Comments
Jim Clemmer
"We delivered a strong quarter, driven by continued execution across the organization, allowing us to deliver yet another quarter of profitable growth," commented Jim Clemmer, President and Chief Executive Officer of AngioDynamics, Inc. "Our mechanical thrombectomy portfolio exhibited standout performance as commercial adoption continues to build with both AlphaVac and AngioVac, confirming our belief that we have the strongest mechanical thrombectomy portfolio available. Auryon remains a consistent growth driver, and NanoKnife is accelerating adoption as we see our commercial strategy supported by the recently effective CPT 1 code for prostate. Beyond the demonstrated topline growth in our higher margin Med Tech businesses, the disciplined execution of our operating initiatives translated into another quarter of strong positive adjusted EBITDA." Mr. Clemmer continued, "Our year-to-date performance gives us confidence in our ability to continue to deliver on our strategy and vision. The progress we have made over the past several years is showing up in our results, and we remain focused on driving sustained, profitable growth as we head into the fourth quarter and fiscal 2027."
Informational and educational content only. Not investment advice.